ANDA 217329, held by Annora Pharma. Fostamatinib Disodium.
As of Nov 16, 2026, ANDA 217329 (Fostamatinib Disodium), held by Annora Pharma, was first approved by FDA on Jun 17, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 17, 2026 | Original application | Approved |
| Fostamatinib DisodiumEQ 100MG BASE · tablet;oral | Fostamatinib Disodium | Rx |
| Fostamatinib DisodiumEQ 150MG BASE · tablet;oral | Fostamatinib Disodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters